Introduction
Carriers of BRCA1 and BRCA2 mutations are at increased risk for multiple malignancies, especially breast and ovarian cancer. Cumulative breast cancer risks by age 70 are estimated to be 65% for BRCA1 and 45% for BRCA2 mutation carriers.
Only 5-10% of invasive breast cancer (IBC) cases result from an autosomal dominant predisposition, but the prevalence of BRCA mutations is higher in young women and in women from populations with founder mutations.
1 For example, 1 in 40 Ashkenazi
Jewish (AJ) individuals carry a founder mutation in the BRCA1 or BRCA2 gene.
2
Among AJ women diagnosed with breast cancer before the age of 40, 13-43% carry BRCA mutations.
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The incidence of ductal carcinoma in situ (DCIS), which is usually asymptomatic, has risen dramatically over the past 20 years due to the widespread use of screening mammography. The association of BRCA mutations with IBC is well established, but some controversy exists regarding whether DCIS should be considered a component of the BRCA-associated Hereditary Breast-Ovarian Cancer Syndrome (HBOCS). An early epidemiologic study reviewing 36 families with BRCA1 mutations found only four cases of DCIS. 6 Subsequent studies evaluating pathological specimens from women with sporadic and BRCA mutation-associated IBC found less DCIS associated with the invasive cancers in the BRCA1 mutation carriers than the sporadic cases. [7] [8] [9] These studies have led to the suggestion that the pre-invasive phase may be shortened or even absent in hereditary breast cancers, particularly those associated with BRCA1 mutations. 8 The identification of DCIS in risk-reducing mastectomy specimens from women with BRCA mutations and in biopsies done in response to abnormal screening studies 
Materials and Methods
BRCA mutation prevalence was determined in three groups of women. The first two groups were prevalent (group 1) and incident (group 2) hospital-based ascertainments of AJ women with DCIS. Group 3 was a clinic-based ascertainment of AJ and non-AJ women with DCIS who presented to a hereditary cancer risk assessment service.
All ascertainment and de-identification procedures were approved by the Memorial 
Clinic-based ascertainment
The characteristics of the 79 DCIS probands in the clinical ascertainment are displayed in Table 2 . Of note, 45.6% had a FH of early onset breast cancer and 17.8% had a FH of OC. The mean age of diagnosis of DCIS was 46.9 (range 24-75). Among the 79 probands, 10 were found to have deleterious BRCA mutations (12.7%) and 2 were found to have variants of uncertain significance (2.5%). Seven of the 10 deleterious mutations identified were in BRCA1 while 3 were in BRCA2.
Deleterious mutations were identified in 5 of 42 AJ probands (11.9%) and in 5 of 37 non-AJ probands (13.5%) (p=1.00). Deleterious mutations were identified in 7 of 56 probands ≤ 50 years old (12.5%) and in 3 of 23 probands >50 years old (13.0%) at diagnosis of DCIS (p=1.00). In comparison, deleterious mutations were identified in 282 (14%) of 2,002 women with IBC seen during this same period, including 222/1,281 (17%) of those with IBC before age 50 (Table 1) . Table 4) .
Discussion
The present study suggests that a diagnosis of IBC is more suggestive of an underlying BRCA mutation than a diagnosis of DCIS. In the nested case-control studies of AJ women with DCIS not selected for FH or age at diagnosis, mutations were identified in 2.5%, significantly lower than the frequency of mutations in age-matched controls with invasive cancer. Indeed, the prevalence of mutations in AJ women with DCIS was similar to the 1.8% (62/3434) observed by Hartge et al. in AJ volunteers without a diagnosis of breast or ovarian cancer. 21 This suggests that AJ founder mutations are not associated with an increased risk of DCIS in women who are not selected for early-onset disease or FH of breast or ovarian cancer, but the small sample size and lack of formal age-matching limits the ability to reach a definitive conclusion. In particular, very few women with early-onset DCIS were included in the unselected ascertainment, reflecting the usual age distribution of this disease.
In the clinic-based ascertainment of women with DCIS, in whom the mean age at diagnosis was lower, and a FH of OC and/or early onset breast cancer was common,
BRCA mutations were identified in 12.7% of probands (11.9% of AJ and 13.5% of non-AJ women). This is consistent with the frequency of 13% in women with DCIS diagnosed before age 50 in a retrospective analysis of 10,000 consecutive patients referred for genetic testing, and slightly less than the 17% (222 of 1,281) prevalence of BRCA mutations observed among women with IBC before age 50 referred for genetic testing at our institution during this same period. 18 This comparison is limited by several factors. Pathology reports confirming invasive disease were not available for all of the women with IBC, and misclassification bias could affect the comparison.
Also, during the interval covered by this study, AJ ethnicity was slightly less common in women undergoing testing for IBC at our institution (49%) than in the DCIS cases reported here (53%). AJ ethnicity was not associated with an increased prevalence of The present study has certain limitations. For the nested case-control studies, prevalent and incident ascertainments were combined to improve power. As survival from DCIS approaches 100%, there is no obvious reason to suspect significant differences in mutation prevalence between incident and prevalent cohorts, but larger sample sizes would be required to exclude such an effect. Family history information was not available for the unselected groups, which also limits the conclusions that 3 chapter can be drawn. In the clinical ascertainment, some of the AJ probands only underwent testing for AJ founder mutations while others also underwent full sequencing. It is possible that some non-founder mutations were missed in the probands for whom full sequencing was not performed, however the number of such mutations is unlikely to be high enough to affect the conclusions. Finally, self-report was used to determine FH, a practice which may be subject to error.
This study indicates that women presenting for hereditary risk assessment with a personal history of DCIS may be found to carry BRCA mutations, particularly if they have significant family histories of ovarian cancer or early-onset breast cancer. The findings support, but do not prove, the presence of an in situ phase of carcinogenesis in the development of at least some BRCA-associated breast cancers. This emphasizes the potential benefit of screening in mutation carriers, which may identify cancers while in an in situ phase. The comparatively lower prevalence of mutations in women with DCIS compared to those with invasive cancer suggests that a pre-invasive phase,
if it exists, may be shortened in a significant proportion of BRCA-associated breast cancers. Clinical trials to evaluate the benefit of screening at more frequent (e.g. semiannual) intervals may address this possibility.
